Linked Life Data

16141930

Source:http://linkedlifedata.com/resource/pubmed/id/16141930

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-9-5
pubmed:abstractText
Vigabatrin is a GABA mimetic antiepileptic agent that has been used for 10 years in cases of epilepsy that resist other treatments. Since 1997, concentric visual field defects have been reported. Before any visual symptom complaint, they quickly become irreversible and highly disabling. To prevent this visual impairment, the monitoring protocol must be defined with reliable and well-supported tests, so that patients treated with Vigabatrin can be regularly monitored. Our purpose was to know if EOG impairments were frequent, if their severity was proportional to visual impairment, and if the Arden ratio could be a predictive criterion of Vigabatrin toxicity. Seventy-two patients treated with Vigabatrin for 2-10 years were examined, and EOG results were compared with a normal population EOG and then the patient's visual field. The monitoring protocol proposed includes EOG, which seems to be the most sensitive and specific diagnostic tool for screening Vigabatrin-treated patients.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0181-5512
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
635-41
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
[Electrophysiological monitoring of epileptic patients treated with Vigabatrin].
pubmed:affiliation
Unité d'Electrophysiologie, CHNO des Quinze-Vingts, Paris.
pubmed:publicationType
Journal Article, English Abstract